Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension
AssigneeLiquidia Technologies, Inc.
InventorsRobert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
Life of this patent
Estimating the term…
Abstract
A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
Claims25
-27. (canceled)
A system for administrating treprostinil or a pharmaceutically acceptable salt thereof to a patient, the system comprising:
- a dosage unit containing a predetermined amount of dry powder particles wherein at least about 78 percent of the dry powder particles when aerosolized have a diameter less than 4 μm, the dry powder particles comprising treprostinil or a pharmaceutically acceptable salt thereof;
- and
- a dry powder inhaler.
Dependencies are inferred from the claim text.